Format

Send to

Choose Destination
Lung Cancer. 2003 Aug;41 Suppl 1:S89-96.

Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.

Author information

1
Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA. pcmack@ucdavis.edu

Abstract

PS-341, a potent and selective proteasome inhibitor, is the prototype for a new class of therapeutics that targets the ubiquitin-proteasome pathway. It is active as a single agent and potentiates chemotherapy and radiation in pre-clinical models. Early phase clinical studies have demonstrated tolerability and activity in multiple myeloma, lymphoma, prostate cancer and lung cancer. By its mechanism of inhibiting protein degradation, PS-341 targets a wide-range of pathways that are relevant to tumor progression and therapy resistance, and can directly modulate expression of cyclins, p27(Kip1), p53, NF-kappaB, Bcl-2 and Bax. PS-341 is currently in phase I/II clinical development in lung cancer. This paper will review the pre-clinical and clinical experience with PS-341 as it relates to lung cancer.

PMID:
12867067
DOI:
10.1016/s0169-5002(03)00149-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center